Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha)

NCT04941261 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

1716

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus Infections
Norwalk Gastroenteritis

Interventions

BIOLOGICAL: middle-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
BIOLOGICAL: high-dose Norovirus Bivalent (GI.1 / GII.4) Vaccine
BIOLOGICAL: placebo

Sponsor

National Vaccine and Serum Institute, China

Collaborators

[object Object]
[object Object]
[object Object]